Trial Profile
Effect of Intravaginal Prasterone (DHEA) on Moderate to Severe Symptoms of Vulvovaginal Atrophy Due to Menopause, in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer - (Placebo-Controlled, Double Blind and Randomized Phase III Study)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 03 Aug 2020
Price :
$35
*
At a glance
- Drugs Prasterone (Primary)
- Indications Atrophic vaginitis
- Focus Registrational; Therapeutic Use
- Sponsors Endoceutics
- 29 Jul 2020 Planned End Date changed from 1 Jun 2021 to 5 Dec 2019.
- 29 Jul 2020 Planned primary completion date changed from 1 Mar 2021 to 5 Dec 2019.
- 29 Jul 2020 Planned initiation date changed from 1 Nov 2019 to 6 Nov 2018.